JP2013144697A5 - - Google Patents

Download PDF

Info

Publication number
JP2013144697A5
JP2013144697A5 JP2013044384A JP2013044384A JP2013144697A5 JP 2013144697 A5 JP2013144697 A5 JP 2013144697A5 JP 2013044384 A JP2013044384 A JP 2013044384A JP 2013044384 A JP2013044384 A JP 2013044384A JP 2013144697 A5 JP2013144697 A5 JP 2013144697A5
Authority
JP
Japan
Prior art keywords
insulin
composition according
carrier
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013044384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013144697A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013144697A publication Critical patent/JP2013144697A/ja
Publication of JP2013144697A5 publication Critical patent/JP2013144697A5/ja
Pending legal-status Critical Current

Links

JP2013044384A 2007-07-30 2013-03-06 医薬組成物 Pending JP2013144697A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96270607P 2007-07-30 2007-07-30
US60/962,706 2007-07-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010518808A Division JP5411857B2 (ja) 2007-07-30 2008-07-30 医薬組成物及び関連方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013221921A Division JP2014024862A (ja) 2007-07-30 2013-10-25 医薬組成物

Publications (2)

Publication Number Publication Date
JP2013144697A JP2013144697A (ja) 2013-07-25
JP2013144697A5 true JP2013144697A5 (enExample) 2013-12-12

Family

ID=40305016

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010518808A Expired - Fee Related JP5411857B2 (ja) 2007-07-30 2008-07-30 医薬組成物及び関連方法
JP2013044384A Pending JP2013144697A (ja) 2007-07-30 2013-03-06 医薬組成物
JP2013221921A Pending JP2014024862A (ja) 2007-07-30 2013-10-25 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010518808A Expired - Fee Related JP5411857B2 (ja) 2007-07-30 2008-07-30 医薬組成物及び関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013221921A Pending JP2014024862A (ja) 2007-07-30 2013-10-25 医薬組成物

Country Status (10)

Country Link
US (3) US20100310542A1 (enExample)
EP (2) EP2653166A3 (enExample)
JP (3) JP5411857B2 (enExample)
KR (2) KR20100040912A (enExample)
CN (2) CN101835486B (enExample)
AU (1) AU2008281374B2 (enExample)
CA (1) CA2694927A1 (enExample)
NZ (1) NZ582556A (enExample)
RU (2) RU2502520C2 (enExample)
WO (1) WO2009016629A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
WO2011011808A1 (en) * 2009-07-30 2011-02-03 Roman Buga A cosmetic composition comprising sodium chloride in combination with one or more of protein, collagen, gelatin or amino acid
US8889615B2 (en) 2009-12-31 2014-11-18 New York University Methods for promoting epithelialization and healing of chronic wounds
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
CN104758921A (zh) * 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
US10342891B2 (en) * 2013-09-19 2019-07-09 Medline Industries, Inc. Wound dressing containing saccharide and collagen
BR112016017444A2 (pt) * 2014-01-29 2017-10-10 Inst Nat Sante Rech Med molécula e método
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549747A (en) * 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3947573A (en) * 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3767788A (en) * 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) * 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3987163A (en) * 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US3907985A (en) * 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) * 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) * 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4558033A (en) * 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
EP0223977B1 (en) * 1985-11-25 1990-10-10 Wako Pure Chemical Industries, Ltd. Colour developing method in clinical examinations
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
JPH0739508B2 (ja) * 1986-11-11 1995-05-01 株式会社林原生物化学研究所 プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5137734A (en) * 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5723119A (en) * 1989-07-28 1998-03-03 Schering Corporation Method for enhancing wound healing/repair with IL-4
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
DE69229779T2 (de) * 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
US6537973B1 (en) * 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US6028118A (en) * 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5631245A (en) * 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
EP0877752B1 (en) * 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6489306B2 (en) * 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6096288A (en) * 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
US7074408B2 (en) * 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
HUP0300347A3 (en) * 2000-03-24 2005-03-29 Novartis Ag Improved treatment of neovascularization
US6582713B2 (en) * 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
JP2004536018A (ja) * 2000-07-31 2004-12-02 バル・イラン・ユニバーシティ 創傷治療のための方法および薬学的組成物
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US20020119914A1 (en) * 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
JP2002198443A (ja) * 2000-12-26 2002-07-12 Nec Corp 半導体装置及びその製造方法
GB0103877D0 (en) * 2001-02-16 2001-04-04 King S College London Novel Drug Delivery system
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
KR100404072B1 (ko) * 2001-03-12 2003-11-03 주식회사 두산 광범위 피부질환 치료용 조성물
US20030091601A1 (en) * 2001-11-13 2003-05-15 Abat Inc. Use of topical arginine to enhance wound healing
US20030124503A1 (en) * 2001-12-28 2003-07-03 Olivencia-Yurvati Albert H. Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
AU2003209226A1 (en) * 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
RU2249467C2 (ru) * 2002-11-25 2005-04-10 ООО Научно-производственное предприятие "ЭРЛОН", Лтд. Медицинский материал и изделия на его основе
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7190893B2 (en) * 2003-06-27 2007-03-13 Valeo Electrical Systems, Inc. Fluid heater with low porosity thermal mass
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
ES2375565T3 (es) * 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
KR20060127415A (ko) * 2003-12-24 2006-12-12 와이어쓰 천식의 치료방법
WO2005079300A2 (en) * 2004-02-13 2005-09-01 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
CA2659961A1 (en) * 2005-08-05 2007-02-15 Pharmagap Inc. Targeted protein kinase c inhibitors and uses thereof
WO2007022532A2 (en) * 2005-08-19 2007-02-22 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
US20110223177A1 (en) * 2008-09-09 2011-09-15 University Of East Anglia Treatment of fibrotic eye disorders
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions

Similar Documents

Publication Publication Date Title
HRP20211415T1 (hr) Brzodjelujući pripravci inzulina
AR134413A2 (es) Composiciones de insulina de rápida acción
AR102869A1 (es) Composiciones de insulina de rápida acción
PE20151786A1 (es) Compuestos heterociclicos y sus usos
PH12015502441B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
WO2017100700A3 (en) Peptides for renal therapy
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
CL2013002166A1 (es) Compuesto correspondiente a la sal de magnesio del acido (s)-alfa-etoxi-4-[2-metil-5-[4-metiltiofenil-1h-pirrol-1-il]etoxi]bencenpropanoico; composicion farmaceutica que lo comprende; y uso para el tratamiento de lipodistrofia.
AR102438A1 (es) Composiciones en aerosol para antitranspirante anhidro, método de fabricación y uso
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
PE20171334A1 (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia
JP2014218522A5 (enExample)
MX374958B (es) Sal de cloruro de tat-nr2b9c.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
JP2013532677A5 (enExample)
NI201500118A (es) Imidazopiridazinas sustituidas
HRP20201948T1 (hr) Pripravci inhibitora dopa-dekarbokilaze
PE20141265A1 (es) Formulaciones liofilizadas de fgf-18
PH12014502366B1 (en) Injectable formulation
MX2016011358A (es) Composiciones liquidas de lactasa.
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
ECSP14013328A (es) Preparacion de liberacion sostenida
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PE20140962A1 (es) Una formulacion farmaceutica solida